Research programme: lantibiotics - Sentinella Pharmaceuticals

Drug Profile

Research programme: lantibiotics - Sentinella Pharmaceuticals

Alternative Names: Nai 107; NAI 112; Nai 112; NAI 802; NAI-107

Latest Information Update: 21 Mar 2016

Price : $50

At a glance

  • Originator NAICONS
  • Developer Sentinella Pharmaceuticals
  • Class Peptides
  • Mechanism of Action Cell wall inhibitors; TRPV cation channel modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Gram-positive infections; Neuropathic pain

Most Recent Events

  • 21 Mar 2016 Preclinical development for Gram-positive infections is ongoing in USA
  • 02 Dec 2015 Preclinical trials in Neuropathic pain in USA (unspecified route)
  • 19 Sep 2011 Preclinical pharmacodynamics and pharmacokinetics data presented at the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC-2011)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top